Progression of Gestational Subclinical Hypothyroidism and Hypothyroxinemia to Overt Hypothyroidism After Pregnancy: Pooled Analysis of Data from Two Randomized Controlled Trials
- PMID: 39028022
- PMCID: PMC11563732
- DOI: 10.1089/thy.2023.0616
Progression of Gestational Subclinical Hypothyroidism and Hypothyroxinemia to Overt Hypothyroidism After Pregnancy: Pooled Analysis of Data from Two Randomized Controlled Trials
Abstract
Background: To examine the incidence of overt hypothyroidism 1 and 5 years after pregnancies where screening before 21 weeks identified subclinical hypothyroidism (SH) or hypothyroxinemia (HT). Methods: Secondary analysis of two multicenter treatment trials for either SH or HT diagnosed between 8 and 20 weeks gestation. Current analyses focus only on individuals randomized to the placebo groups in the two parallel studies. SH was diagnosed with thyrotropin (TSH) ≥4.0 mU/L and normal free T4 (fT4) (0.86-1.9 ng/dL). HT was diagnosed with normal TSH (0.08-3.99 mU/L) but fT4 <0.86 ng/dL. Serum from initial testing was stored for later thyroid peroxidase (TPO) antibody assay; results were not returned for clinical management. At 1 and 5 years after delivery, participants were asked whether they had either been diagnosed with or were being treated for a thyroid condition. Maternal serum was collected at these visits and thyroid function measured. Subsequent overt hypothyroidism was defined as TSH ≥4.0 mU/L with fT4 <0.86 ng/dL. Results: Data for 1- and 5-year follow-up were available in 307 of the 338 participants with SH and 229 of the 261 with HT. Subsequent hypothyroidism was more common both at year 1 (13.4% vs. 3.1%, p < 0.001) and year 5 (15.6% vs. 2.6%, p < 0.001) for participants with SH compared with those with HT. This progression was more common in individuals with TSH values >10 mIU/mL. Baseline TPO level >50 IU/mL in participants with SH was associated with higher rates of hypothyroidism at year 1 (26.7% vs. 6.5%, odds ratio [OR] = 5.3 [confidence interval (CI) 2.6-10.7]) and year 5 (30.5% vs. 7.5%, OR = 5.4 [CI: 2.8-10.6]) compared with those with TPO levels ≤50 IU/mL. For participants with HT, no differences in overt hypothyroidism were seen at 1 year related to baseline TPO level >50 IU/mL (1/10 (10%) vs. 6/218 (2.8%), OR = 3.9 [CI: 0.43-36.1]), but more participants with TPO levels >50 IU/mL developed hypothyroidism by year 5 (2/10 (20%) vs. 4/218 (1.8%), OR = 13.4 [CI: 2.1-84.1]). Conclusion: SH is associated with higher rates of overt hypothyroidism or thyroid replacement therapy within 5 years of delivery than is HT when these conditions are diagnosed in the first half of pregnancy.
Keywords: pregnancy; thyroid and pregnancy; thyroid epidemiology.
Similar articles
-
Screening and subsequent management for thyroid dysfunction pre-pregnancy and during pregnancy for improving maternal and infant health.Cochrane Database Syst Rev. 2015 Sep 21;2015(9):CD011263. doi: 10.1002/14651858.CD011263.pub2. Cochrane Database Syst Rev. 2015. PMID: 26387772 Free PMC article.
-
Effects of Levothyroxine Treatment on Fertility and Pregnancy Outcomes in Subclinical Hypothyroidism: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.Thyroid. 2024 Apr;34(4):519-530. doi: 10.1089/thy.2023.0546. Thyroid. 2024. PMID: 38368537
-
Iodine supplementation for women during the preconception, pregnancy and postpartum period.Cochrane Database Syst Rev. 2017 Mar 5;3(3):CD011761. doi: 10.1002/14651858.CD011761.pub2. Cochrane Database Syst Rev. 2017. PMID: 28260263 Free PMC article.
-
Thyroid Function Within the Normal Range, Subclinical Hypothyroidism, and the Risk of Atrial Fibrillation.Circulation. 2017 Nov 28;136(22):2100-2116. doi: 10.1161/CIRCULATIONAHA.117.028753. Epub 2017 Oct 23. Circulation. 2017. PMID: 29061566 Free PMC article.
-
Levothyroxine Treatment in Pregnant Women with Thyrotropin Levels Ranging Between 2.5 and 10 mIU/L: A Propensity Score Matched Analysis.Thyroid. 2024 Jul;34(7):912-919. doi: 10.1089/thy.2023.0662. Epub 2024 May 9. Thyroid. 2024. PMID: 38666684
Cited by
-
Summary of the Year in Review Lectures at the 2024 Annual Meeting of the American Thyroid Association.Thyroid. 2025 Feb;35(2):123-130. doi: 10.1089/thy.2024.0735. Epub 2025 Jan 28. Thyroid. 2025. PMID: 39873525 No abstract available.
-
Risk of Progression of Gestational Subclinical Hypothyroidism and Hypothyroxinemia to Overt Hypothyroidism After Pregnancy is Associated with Underlying Thyroid Autoimmunity.Thyroid. 2024 Sep;34(9):1066-1067. doi: 10.1089/thy.2024.0435. Epub 2024 Aug 16. Thyroid. 2024. PMID: 39104251 No abstract available.
References
-
- American College of Obstetricians and Gynecologists. Thyroid disease in pregnancy: ACOG Practice Bulletin No. 223. Obstet Gynecol 2020;135:e261–74. - PubMed
-
- Haddow JE, Palomaki GE, Allan WC, et al. . Maternal thyroid deficiency during pregnancy and subsequent neuropsychological development of the child. N Engl J Med 1999;341(8):549–555. - PubMed
-
- Wang C, Crapo LM. The epidemiology of thyroid disease and implications for screening. Endocrinol Metab Clin North Am 1997;26(1):189–218. - PubMed
-
- Manji N, Carr-Smith JD, Boelaert K, et al. . Influences of age, gender, smoking, and family history on autoimmune thyroid disease phenotype. J Clin Endocrinol Metab 2006;91(12):4873–4880. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials